Why the study?
Athletes competing in track and field at the international level may have underlying undiagnosed life-threatening cardiovascular conditions.
What is the prevalence of pre-participation cardiac evaluation among athletes competing in World Athletics Championships?
What is the prevalence of pre-participation cardiac evaluation among athletes competing in World Athletics Championships?
There is a significant global disparity in pre-participation cardiac evaluation among elite athletes, highlighting the need for cost-effective screening methods in low- to middle-income countries.
Variations in screening prevalence by country development may heighten undetected risks for some athletes; leaves open whether global equity initiatives can close gaps.
BACKGROUND: Athletes competing in athletics (track and field) at international level may be participating with underlying undiagnosed life-threatening cardiovascular conditions. Our objective was to analyse variations in pre-participation cardiac evaluation prevalence among athletes participating in two International Association of Athletics Federations (IAAF) World Athletics Championships, with regard to the human developmental level and global region of their home countries, as well as athletes' age category, gender, event group and medical insurance type. DESIGN: Cross-sectional web-based survey. METHODS: A total of 1785 athletes competing in the IAAF World Under 18 Championships Nairobi 2017 and World Championships London 2017 were invited to complete a pre-participation health questionnaire investigating the experience of a pre-participation cardiac examination. RESULTS: A total of 704 (39%) of the athletes participated. Among these, 59% (60% of women; 58% of men) reported that they had been provided at least one type of pre-participation cardiac evaluation. Athletes from very high income countries, Europe and Asia, showed a higher prevalence of at least one pre-participation cardiac evaluation. CONCLUSIONS: The prevalence of pre-participation cardiac evaluation in low to middle income countries, and the African continent in particular, needs urgent attention. Furthermore, increases in evaluation prevalence should be accompanied by the development of cost-effective methods that can be adopted in all global regions.
No takes yet. Share an insight, caveat, or question.
Dahlström et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: